… significant activation of the coagulation system in small cell lung cancer and of the
fibrinolysis system in non-small-cell lung cancer in those who did not respond to chemotherapy. …

… applications of the tumour markers CYFRA 21-1, SCC antigen, NSE, and CEA in patients
with lung cancer. Due to the rather low prevalence of bronchogenic carcinoma in the general …

… cells/samples (range: 0-1). We are also able to detect CTCs in 138 cases (79.31%) from the
174 lung cancer patients in this study, with a median of 2 cells/… between lung cancer patients …

… progression and a prognostic marker in colorectal and ovarian cancers. In this first
comprehensive review of immune markers of non–small cell lung cancer (NSCLC) in (i) the tumor …

… from the patients with non-small cell lung cancer (n = 120), benign pulmonary disease (n
= 106) and from healthy subjects (n = 80) so as to further investigate their relationship with …

… tumor markers and … marker in lung cancer but with no relationship to histology, in contrast
to the association with squamous tumors that has been suggested [8, 9]. Other tumor markers …

… cell lines examined. In addition, these markers were detectable in less than 10% of 46 lung
cancer … By contrast, Heighway et al.35 recently studied NSCLC samples from 39 patients and …

… NSE, SCC and CEA in patients with SCLC and with non-small-cell lung cancer; (2) evaluate
… (3) assess whether there is any correlation between tumour stage and serum marker levels. …

… to evaluate the clinical significance of the tumor markers TPS, CYFRA 21-1, … patients with
lung cancer and to study the diagnostic utility and the predicting ability of these tumor markers …

… This study has confirmed the utility of NSE as a sensitive marker for small cell lung cancer
and demonstrated its preeminent prognostic significance in multivariate analysis for remission …